From GlobeNewswire: 2025-05-14 16:30:00

Calidi Biotherapeutics Inc. made key hires for CEO and CMO with biopharmaceutical experience. IL15-superagonist selected as first payload for Redtail platform. FDA cleared IND for CLD-201 clinical trial targeting solid tumors. First quarter 2025 financial results showed a net loss of $5.0 million. Calidi is focused on developing systemic oncolytic targeted immunotherapies.



Read more at GlobeNewswire:: Calidi Biotherapeutics Reports First Quarter 2025 Financial